11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

Abstract Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiati...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Radek Lakomý, Martina Lojová, Lenka Souckova, Ludmila Hynkova, Katerina Polachova, Jiri Vasina, Regina Demlová, Alexandr Poprach, Jiri Sana, Tomas Prochazka, Martin Smrcka, Pavel Fadrus, Radim Jancalek, Iveta Selingerova, Renata Belanova, Pavel Slampa, Petr Pospisil, Tomas Kazda
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Glioblastoma Rapid early progression Radiopharmaceutical 11C-methionine Clinical trial Positron emission tomography
Online Access:	https://doi.org/10.1186/s12885-024-12469-2